Chlamydia Infection Diagnostics Market Report 2026

The chlamydia infection diagnostics market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to expansion of laboratory infrastructure, rising incidence of chlamydia infections, increased use of molecular diagnostics, growth in clinical testing volumes, availability of standardized diagnostic protocols.

The chlamydia infection diagnostics market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for rapid and automated diagnostics, rising investments in laboratory automation, expansion of decentralized diagnostic testing, growing focus on early infection detection, continuous innovation in molecular testing technologies. Major trends in the forecast period include increasing deployment of advanced molecular diagnostic platforms, rising adoption of pcr and lamp-based tests, growing integration of automation in diagnostic laboratories, expansion of high-throughput screening capabilities, enhanced focus on diagnostic accuracy and speed.

The increasing emphasis on preventive healthcare is anticipated to drive the growth of the chlamydia infection diagnostics market in the coming years. Preventive healthcare refers to actions taken to avoid diseases before they develop, including regular health screenings, vaccinations, and lifestyle interventions. The growing focus on preventive healthcare is intended to lower overall healthcare costs, enhance quality of life, and reduce the burden of disease through early identification and proactive management. In the context of chlamydia diagnostics, preventive healthcare is essential as it prioritizes early detection, public awareness, and routine screening, which together help limit disease transmission and prevent long-term complications associated with untreated infections. For instance, in May 2023, according to the National Health Service (NHS), a UK-based publicly funded healthcare system, approximately 23.02 million diagnostic tests were performed in March 2023, representing an increase of 223,100 tests compared with March 2022. Additionally, in March 2023, the number of patients awaiting a key diagnostic test reached 16.28 million, an increase of 59,400 compared to March 2022. Therefore, the growing focus on preventive healthcare is fueling the growth of the chlamydia infection diagnostics market.

Major companies operating in the chlamydia infection diagnostics market are concentrating on the development of advanced solutions, such as molecular point-of-care testing platforms, to strengthen their competitive position. Molecular point-of-care testing platforms are diagnostic systems designed to identify specific nucleic acids, such as DNA or RNA, of pathogens directly at the site of patient care. For instance, in May 2024, Sherlock Biosciences, a US-based biotechnology company, announced the development of the Sherlock test, one of the first disposable molecular diagnostic tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test delivers results in under 30 minutes by analyzing DNA and RNA from self-collected penile meatal or vaginal swab samples.

In December 2023, Imaware, a US-based digital health company, acquired the consumer testing business of Binx Health for an undisclosed amount. Through this acquisition, Imaware aims to reinforce its leadership in sexually transmitted infection screening, broaden its consumer diagnostic portfolio, improve access to at-home testing solutions, and accelerate growth within the sexual health market. Binx Health is a US-based healthcare company that specializes in providing at-home diagnostic solutions for sexually transmitted infections.

Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics.

North America was the largest region in the chlamydia infection diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chlamydia infection diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chlamydia infection diagnostics market by increasing costs of imported molecular testing equipment, reagents, consumables, and analytical software. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported diagnostic platforms, while Asia-Pacific faces cost pressure on test kit exports. These tariffs are increasing per-test costs and delaying technology upgrades. However, they are also promoting local manufacturing of diagnostic instruments and regional development of cost-effective testing solutions.

The chlamydia infection diagnostics market research report is one of a series of new reports that provides chlamydia infection diagnostics market statistics, including chlamydia infection diagnostics industry global market size, regional shares, competitors with a chlamydia infection diagnostics market share, detailed chlamydia infection diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics industry. This chlamydia infection diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chlamydia infection diagnostics refer to the methods and procedures used to detect and confirm the presence of Chlamydia trachomatis bacteria in individuals suspected of having a chlamydial infection. These diagnostic tests are essential for accurate diagnosis, effective treatment planning, and the prevention of further disease transmission.

The main test types for chlamydia infection diagnostics include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, and others. A culture test is a diagnostic method in which patient samples are grown under controlled laboratory conditions to identify the presence of microorganisms, supporting infection diagnosis and treatment selection. These tests are used to detect various forms of chlamydia infections, including genital, rectal, and ocular chlamydia. Diagnostic applications are carried out in hospitals, specialty clinics, and diagnostic centers, and the tests are utilized by end users involved in diagnostics and therapeutics.

The chlamydia infection diagnostics market includes revenues earned by entities by providing services such as laboratory testing services, point-of-care testing, and consultation and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.